Hep B core Antibody
(Specimen Container)
SST (Tiger Top) Lithium Heparin/ Sodium Heparin/ Dipotassium EDTA
(Transport Temperature)
| Temperature | Period |
|---|---|
| Room temperature | 72 hours |
| Refrigerated | 7 days |
| Frozen | If delayed longer than the max RT or 2-8°C, store frozen |
The Alinity i Anti-HBc assay utilizes microparticles coated with recombinant hepatitis B virus core antigen (rHBcAg) for the detection of anti-HBc antibodies. Anti-HBc antibody determinations can be used as an indicator of current or past HBV infection. Anti-HBc antibodies are found in serum shortly after the appearance of hepatitis B surface antigen (HBsAg) in acute HBV infections. They will persist after the disappearance of HBsAg and before the appearance of detectable antibody to HBsAg (anti-HBs). In the absence of information about any other HBV markers, it must be considered that an individual with detectable levels of anti-HBc antibodies may be actively infected with HBV or that the infection may have resolved, leaving the person immune. Anti-HBc antibodies may be the only serological marker of HBV infection and potentially infectious blood.
The presence of anti-HBc antibodies does not differentiate between acute or chronic hepatitis B infection.
The Alinity i Anti-HBc assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgG and IgM antibodies to hepatitis B core antigen (anti-HBc) in human adult and pediatric serum and plasma (dipotassium EDTA, lithium heparin, sodium heparin) and neonatal serum on the Alinity i analyzer.
The Alinity i Anti-HBc assay is to be used as an aid in the diagnosis of acute, chronic, or resolved hepatitis B virus (HBV) infection in conjunction with other laboratory results and clinical information.
WARNING: Not intended for use in screening blood, plasma or tissue donors. The effectiveness of the Alinity i Anti-HBc assay for use in screening blood, plasma, or tissue donors has not been established.
Assay performance characteristics have not been established when the Alinity i Anti-HBc assay is used in conjunction with other manufacturers’ assays for specific hepatitis markers. Users are responsible for establishing their own performance characteristics. Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients. Users are responsible for establishing their own assay performance characteristics in these populations.
No quantitative reference range
